This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
NuVasive Announces Vertera Spine Buyout, Boosts Implants Suite
by Zacks Equity Research
NuVasive (NUVA) to add three-dimensional porous interbody technology across polyetheretherketone (PEEK) material as well through the Vertera Spine buyout.
Chemed Rides on VITAS Recovery, Robust Roto-Rooter Sales
by Zacks Equity Research
Chemed (CHE) steers growth with VITAs business' revival from struggle and Roto-Rooter's consistent rise on the back of core plumbing and drain cleaning service segments.
NuVasive Grows in Pediatric Deformity With New FDA Approval
by Zacks Equity Research
NuVasive (NUVA) has progressed with its 'Embracing the Journey Together' program with the FDA nod to use the company's redesigned MAGEC system with its RELINE Small Stature system.
Abbott (ABT) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Abbott's (ABT) recent FDA approval for Full MagLev HeartMate 3 Left Ventricular Assist Device has boosted investor confidence.
8 Factors That Make Thermo Fisher a Valuable Pick Right Now
by Zacks Equity Research
Based on a wide range of fundamental factors, Thermo Fisher (TMO) is a great pick for now.
Cooper to Benefit From Specialty Lenses Prospects Amid Woes
by Zacks Equity Research
The Cooper Companies' (COO) strong sales growth will continue to be aided by a leading position in the market of specialty lenses.
Align Technology at 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Align Technology's (ALGN) efforts to expand worldwide instil confidence in investors. The market is upbeat about the non-exclusive distribution agreement with Patterson Dental.
Myriad Genetics Boosts myRisk Hereditary Cancer Test Suite
by Zacks Equity Research
Myriad Genetics (MYGN) introduces riskScore, a breast cancer prediction tool to broaden its myRisk hereditary cancer test offerings.
HealthEquity (HQY) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
HealthEquity (HQY) delivered favorable results in the second quarter of fiscal 2018 on the back of revenue and margin expansion.
Henry Schein Joins IMF & LUGFA on Prostate Cancer Awareness
by Zacks Equity Research
Henry Schein (HSIC) joins forces with IMF and LUGPA to generate awareness among physicians and people about the importance of early detection of prostate cancer.
Quest Diagnostics (DGX) Banks on Buyouts, Competition Rife
by Zacks Equity Research
Quest Diagnostics (DGX) witnesses significant growth through infectious disease testing, prescription drug monitoring and wellness business.
4 Large-Cap Medical Device Stocks to Buy Amid Political Woes
by Zacks Equity Research
Investors facing political doldrums can safely place their bets on the Medical Device space on four large-cap medical device stocks that are poised for impressive returns over the next five years.
LabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO
by Zacks Equity Research
In line with its inorganic growth strategy, LabCorp's (LH) latest Chiltern buyout is aimed at promoting the CRO business.
GNC Holdings Gains on New GNC Strength Amid Soft Revenues
by Zacks Equity Research
GNC Holdings (GNC) continues to bank on new GNC plan and global revenues despite lacklustre revenue figures in second quarter of 2017.
Community Health System Divests Hospitals to Lower Debts
by Zacks Equity Research
Community Health Systems, Inc. (CYH) resorts to divestitures in order to finance its long-term debts.
Haemonetics Grows on Strong Plasma, Blood Center Sluggish
by Zacks Equity Research
Haemonetics' (HAE) encouraging growth in both Plasma and Haemonetics Management franchises keeps the market upbeat. However, slow revenue growth at the Blood Center franchise raises concern.
Amedisys to Buy Intercity Home Care, Boosts Personal Care Arm
by Zacks Equity Research
Amedisys (AMED) to strengthen its position in Personal Care business in Massachusetts with this recently signed acquisition deal.
VWR Awaits Merger Closure, Stock Upside Potential Limited
by Zacks Equity Research
VWR Corporation's (VWR) $6.4 billion acquisition by Avantor should create a major consumables-focused solutions and services provider to lucrative life sciences and advanced technologies industries.
Cooper (COO) Poised to Grow on Specialty Lenses Prospects
by Zacks Equity Research
Cooper's (COO) strong sales growth will continue to be aided by its leading position in the markets of specialty lenses.
NuVasive (NUVA) to Expand San Diego Global Headquarters
by Zacks Equity Research
Apart from introducing sophisticated features at the facility, NuVasive (NUVA) plans to open an innovation center of excellence at the San Diego global headquarters.
Edwards Lifesciences (EW) Down 3.3% Since Earnings Report: Can It Rebound?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings about a month ago. What's next for the stock? We take a look at earnings estimates for some clues.
LabCorp Grows on Solid Diagnostics, Currency Woes a Drag
by Zacks Equity Research
Although LabCorp's (LH) Covance drug development business puts up a dull performance, the market is upbeat about its Diagnostics business, which has recently displayed a solid show.
Henry Schein's Merritt Buyout to Boost U.S. Veterinary Arm
by Zacks Equity Research
Henry Schein's (HSIC) acquisition of Merritt Veterinary supplies will brace its existing U.S. animal health business, particularly in the southeastern United States.
LabCorp & Interpace Extend Deal, Boost Cancer Portfolio
by Zacks Equity Research
LabCorp's (LH) agreement to offer Interpace Diagnostics' molecular tests, ThyGenX and ThyraMIR gets renewed and extended for another two years.
C. R. Bard's (BCR) LUTONIX 035 Gets FDA Pre-Market Approval
by Zacks Equity Research
The early market acceptance of the LUTONIX platform has been impressive and C. R. Bard (BCR) is likely to witness an expanded adoption of this technology as the market continues to mature.